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Abstract: Most patients who suffer from symptomatic Gaucher disease will benefit from 
enzyme replacement therapy (ERT) with imiglucerase. The safety profile is excellent, only a 
small percentage of those exposed developing antibodies; similarly, very few patients require 
pre-medication for allergic reactions. Within 3 to 5 years of imiglucerase therapy, best docu-
mented at doses of 30 to 60 units/kg/infusion, hepatosplenomegaly can be expected to be reduced 
so that the liver volume will be maintained at 1 to 1.5 times normal (30% to 40% reduction 
from advent of ERT) and spleen volume to 2 to 8 times normal (50% to 60% reduction from 
advent of ERT). For anemic and thrombocytopenic patients, with 2 to 5 years of imiglucerase, 
hemoglobin levels are expected to be 11 g/dL for women and children and 12 g/dL for 
men; and platelet counts in patients with an intact spleen, depending on the baseline value, 
should approximately be doubled. Bone crises and bone pain but not irreversible skeletal dam-
age will improve in most patients. Nonetheless, some features and some symptomatic patients 
apparently do not respond equally well and/or perhaps inadequately. The benefit for patients 
with the neuronopathic forms is primarily in improved visceral and hematological signs and 
symptoms. There are still several unresolved issues, the high per-unit cost being an important 
one, which have spurred the development of biosimilar enzymes as well as chaperone therapies 
currently in clinical trials.
Keywords: Gaucher disease, enzyme replacement therapy, imiglucerase, substrate reduction 
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Introduction: Gaucher disease is a rare recessive 
disorder
Gaucher disease, the most prevalent glycolipid storage disorder, is a result of the 
genetic defect in the lysosomal enzyme β-glucocerebrosidase, and consequent 
accumulation of substrate, glucocerebroside, in the monocyte-macrophage system.1 
Clinical heterogeneity is attributable, to a large extent, to (∼300) mutations within the 
glucocerebrosidase gene (located at chromosome 1q21);2 however, the importance 
of epigenetic and environmental influences are beginning to be appreciated.3 Three 
clinical forms have been delineated, based on absence (type 1) or presence (types 2 
and 3) of neurological signs4 and categorization of this sort is useful when talking 
about management options and genetic counseling.
Type 1: non-neuronopathic form
Type 1, the non-neuronopathic form, is the most prevalent, with an ethnic predilection 
among Ashkenazi Jews that may be due to a selective advantage which has not yet Biologics: Targets & Therapy 2009:3 408
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been identified.5 Many patients are virtually asymptomatic 
and are diagnosed incidentally.6 Age of onset of symptoms 
and disease course are variable even among patients homo-
zygous for the common N370S (1226G) mutation which is 
considered mild and protective of neurological involvement.7 
Anemia and/or thrombocytopenia are common findings on 
presentation. In children, height retardation may be noted.8 
Osteopenia and Erlenmeyer flask deformity of the distal 
femur are common;9 symptomatic skeletal features are less 
prevalent, including “bone crises”, osteonecrosis of joints, 
and pathological fractures. Various imaging modalities 
assess/quantify bone involvement,10,11 but pre-symptomatic 
prediction of onset and rate of progression of bone disease has 
not been achieved. Lung involvement, especially infiltrative 
disease, is an uncommon but serious complication usually in 
splenectomized patients with liver involvement. Although the 
N370S mutation was considered to confer protection from 
neurological involvement, patients with this mutation may 
be at increased risk for parkinsonism12,13 and/or may develop 
peripheral nerve abnormalities.14,15
Type 2: acute perinatal lethal 
neuronopathic form
Type 2 is a lethal neuronopathic form usually associated 
with compound heterozygosity for a severe mutation and 
a null mutation,16–18 characterized by hypertonic posturing, 
strabismus, trismus, and retroflexion of the head during 
the first 6 months of life and death following aspiration 
pneumonia and/or apnea/laryngospasm by 2 years.19 Massive 
hepatosplenomegaly and lung involvement are usually seen.16
Type 3: sub-acute neuronopathic 
form with three variants
Type 3 is the more heterogeneous neuronopathic form, 
presenting in childhood and characterized by the pathogno-
monic sign of horizontal supranuclear gaze palsy (HSGP).20 
Most patients have at least one L444P (1448C) mutation. 
Sub-classification of this form is based on relative promi-
nence of neurological versus visceral findings.21 Type 3a 
patients exhibit mild-to-moderate hepatosplenomegaly 
and slowly progressive neurologic deterioration; recurrent 
myoclonic seizures are common. Type 3b has aggressive 
visceral involvement but only HSGP; and type 3c is marked 
by homozygosity for the D409H (1342C) mutation, mild 
visceral disease, HSGP, and importantly, progressive and 
fatal calcifications of left heart (mitral and aortic) valves, 
aorta, and other arteries.22
Nonetheless, while it serves the purposes of this review 
to maintain demarcations between disease types to highlight 
the potential effects of therapeutic interventions, one may 
also view Gaucher phenotypes as a continuum of clinical 
manifestations that obscures rigid classifications.23
Surrogate markers to assess  
efficacy of interventions
Although amelioration of disease-specific symptoms and/or 
signs, eg, reduction in hepatosplenomegaly and improved 
blood counts, is a natural measure of efficacy of treatment, 
because of variability of response and/or the extended 
time-course to achieve a measureable response in disease-
specific symptoms, chitotriosidase activity levels which are 
elevated hundreds-fold in Gaucher disease, have been used 
in the past decade as the preferred surrogate marker.24 But, 
because of genetic deficiency of chitotriosidase in ∼6% of the 
population, CCL 18 (PARC) levels are additionally evalu-
ated25 and research is ongoing to indentify novel biomarkers 
that would better predict bony complications. Some clinicians 
use these surrogate markers as a guide to initiation of treat-
ment and/or dosage changes.
Enzyme replacement therapy 
(ERT): the early years
Nearly 50 years ago DeDuve suggested that lysosomal 
storage disease may be treatable by enzyme replacement.26 
With the development of adequate purification techniques, 
glucocerebrosidase was derived from human placental 
tissue;27 subsequent deglycosylation to expose mannose 
residues28 targeted the product to mannose receptors on the 
macrophages.29 Commercialization resulted in the develop-
ment of alglucerase (Ceredase®; Genzyme Inc., Cambridge, 
MA, USA), the placental derivative, which was tested in 
a seminal 9-month clinical trial of 12 patients with type 1 
disease.30 Within the first 5 years of alglucerase, its safety 
and efficacy in improving hemoglobin levels and platelet 
counts, and in reducing splenic and hepatic enlargement 
were affirmed.
In 1994, the human recombinant form, imiglucerase 
(Cerezyme®; Genzyme Inc, Cambridge, MA, USA), was 
approved based on two clinical trials: the first compar-
ing safety and efficacy of imiglucerase with alglucerase, 
at (high-dose) regimen of 60 units/kg body weight/ 
2 weeks;31 the second compared frequency of administra-
tion of imiglucerase, every 2 weeks versus 3 times a week, 
at (low-dose) 15 units/kg body weight.32 Conclusions noted 
no significant differences between and among the groups. Biologics: Targets & Therapy 2009:3 409
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Imiglucerase gradually replaced alglucerase, which is only 
available today for a handful of patients who are unable to 
tolerate imiglucerase.
Assessment modalities to quantify 
change: recommendation to reduce 
use less commonly available resources 
and decrease invasive modalities 
for routine evaluations
At minimum, monitoring disease expression and effects of 
ERT includes serial evaluation of hematological parameters 
and reduction in hepatosplenomegaly. Although ultrasonog-
raphy may be recommended for repeat assessments as the 
least invasive and as having no risk of radiation,33 especially 
in children,34 it is the least used because of issues of reliability 
and reproducibility and the importance of observer experi-
ence. Computed tomography (CT) was universally employed 
in the past,35 and today, magnetic resonance imaging (MRI),36 
especially because of justifiable concerns about radiation with 
periodic assessments is preferred. Similarly, scintigraphy37 
is rarely employed.
The most accurate but least available tool for the bones 
is quantitative chemical shift imaging (QCSI).38
There are several bone and skeletal assessment scores,39–42 
in addition to actual bone densitometry42,43 and bone 
marker42 evaluations. Echocardiography44 is recommended 
for follow-up of pulmonary hypertension. There are also 
specific tools for quality of life45 assessment and cognitive 
function46 which are optimal for clinical trials rather than 
routine evaluations. In children, assessments are age-
appropriate47 and in patients with type 3 disease, cognitive 
functioning48 is important as well.
Based on years of experience, the Gaucher community 
may/should re-consider the need for minutely accurate 
routine spleen and liver volumes (not in clinical trials) and 
rely on physical examination and ultrasonography combined 
with improved hematology and bio-markers for routine 
evaluations of patients.
The Gaucher registry and 
“therapeutic goals”: benchmarks 
for optimal management?
Since 1991, the Genzyme Corporation has sponsored an 
international database of global outcome assessments, the 
International Collaborative Gaucher Group (ICGG). What 
was originally a commitment of the manufacturer to regula-
tory agencies for post-marketing surveillance, has evolved into 
a powerful tool of information about patient care. Published 
reports with ICGG data highlight patient demographics, and 
safety and efficacy of imiglucerase,49 as well as enable regu-
latory adjustments such as addition of type 3 to drug indica-
tions and modification regarding imiglucerase in pregnancy 
(see below). Indirectly, the almost predictable efficacy of 
imiglucerase has resulted in a new tool for assessing outcome. 
Based on ICGG input, the concept of therapeutic goals was 
introduced.50 These benchmarks reflect past experience in 
treated patients registered in the ICGG, but imply that future 
competitors may have to improve upon these outcomes 
to compete/supersede imiglucerase as standard care.
“Therapeutic goals” for ERT
The findings/expectations51 regarding hepatosplenomegaly 
are to reduce and maintain liver volume 1 to 1.5 times normal 
(by 30% to 40% by years 3 to 5 of ERT) and reduce and main-
tain spleen volume 2 to 8 times normal (by 50% to 60% 
by years 2 to 5 of ERT). For achievement of the therapeutic 
goals for anemic and thrombocytopenic patients, the findings/
expectations respectively for hemoglobin are 11 g/dL for 
women and children and 12 g/dL for men; and for platelet 
counts in patients with an intact spleen and depending on 
the baseline value, a 1.5 to 2.0 fold-increase or doubling of 
counts by years 2 to 5 of ERT but not necessarily normaliza-
tion of counts.
More recently, Weinreb et al52 presented the accumulated 
experience of the ICGG registry in achieving the above 
four goals. After 4 years of ERT, the findings in 195 patients 
(who were chosen based on various criteria and of sufficient 
data points but who are claimed to be representative of the 
entire cohort of 4760 patients) in achieving said goals was 
23.6% to 54.9%. There were two additional therapeutic 
goals, reduction in bone pain and bone crises, but it is still 
unclear whether ERT directly impacts these symptoms: most 
patients at baseline do not suffer from bone crises (episodes 
of bone pain that are localized and self-limiting); however, 
many patients suffer chronic bone pain, but achievement of 
this goal was the most modest (7.7%) of the six parameters 
evaluated.52 Nonetheless, other registry-based studies have 
shown significant improvements in bone parameters within 
4 years of ERT.53 Children assessed in a separate study 
showed equally impressive improvements in the visceral 
response and linear growth.54
Therapeutic goals for hemoglobin improvement and liver 
volume reduction ie, the less Gaucher-specific parameters were 
more often met than for splenic volume and platelet counts which 
are more specifically characteristic of Gaucher disease.1Biologics: Targets & Therapy 2009:3 410
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Finally, the impact of alglucerase/imiglucerase on the 
surrogate markers, chitotriosidase55 and CCL 18 (PARC)56 has 
lent credibility to their reliability to track interventions.
ERT for bone disease
Among patients from the seminal alglucerase trial radiological 
evidence of skeletal change was noted only 42 months 
after advent of therapy,57,58 but pathological damages 
(eg, osteonecrosis, bone infarcts, fractures) were not reversed. 
Importantly, improved MRI signals with ERT are not neces-
sarily clinically relevant since no definitive correlation exists 
between MRI findings and incidence/severity of skeletal 
complications such as avascular necrosis.59
The most probable advantage for patients prone 
to bone disease (beyond not undergoing total60 or par-
tial splenectomy),61 is early administration of ERT as 
preventative, especially in children.62 This premise is based 
on fewer cases of avascular necrosis among children born 
after ERT availability relative to children growing up before 
availability of ERT.62 The challenge is still how to identify 
children at risk during the pre-symptomatic stage of the 
disease. This is particularly difficult in patient homozygous 
for the N370S mutation.
Osteopenia is not uncommon in the general population 
but apparently progression to osteoporosis, ie, decreased bone 
mineral density (BMD) as generally estimated by dual-energy 
X-ray absorptiometry (DEXA), is characteristic of adults 
with Gaucher disease.63 Imiglucerase (60 units/kg/2 weeks) 
significantly improves BMD in adult patients with 
improvement of BMD at the lumbar spine64 and femoral 
neck65 after 3 to 4 years. Moreover, biochemical markers 
for bone formation increased, markers for bone resorption 
decreased, with resolution of bone crises, decreased bone 
pain, and fewer skeletal complications.65
In summary, it cannot be said with absolute certainty that 
ERT will prevent or reverse skeletal complications.
Co-administration of imiglucerase 
and alendronate for bone 
involvement
Bisphosphonates are well-documented as effective in 
increasing BMD in at-risk adult populations.66 A clinical trial 
of co-administration of imiglucerase with oral alendronate 
(40 mg/day) in adult patients proved that combined therapy 
was significantly better for Gaucher-related osteopenia rela-
tive to imiglucerase alone, although skeletal lesions remained 
irreversible.67 However, this placebo-controlled prospective 
study unfortunately did not include an alendronate-only arm 
which may have been equally effective. This speculation 
is based on the authors’ experience with osteopenic/
osteoporotic patients without other significant Gaucher-
related signs/symptoms, who have demonstrated impressive 
improvement in BMD using bisphosphonates and calcium 
supplementation alone.
It may be posited therefore that while various facets of 
bone disease in patients with Gaucher disease are specific 
Gaucher signs and theoretically amenable to ERT, there are a 
myriad of epigenetic and environmental factors, comparable 
to those seen in healthy populations,68 that impact a global 
marker such as BMD, and hence ERT would not be expected 
to completely correct all deficits.
Another tenable hypothetical construct is that the large 
enzyme molecules are equally incapable of traversing the 
blood-brain barrier as the small blood vessels of bony matrix 
and/or Gaucher-cell-infiltrated marrow which may have 
the character of immortalized cells and/or dead tissue. Be 
that as it may, preventing bone involvement and reversing 
destructive processes of (type 1 and type 3) Gaucher disease, 
remains unresolved.69
Other uncommon sites 
of Gaucher involvement where 
the effect of enzyme replacement 
is imperfect: lung and brain
The earliest report of ERT in severely affected patients with 
non-neuronopathic disease and infiltrative lung involvement 
reported improved functioning,70 but not always of clinical 
significance.71 Children with type 272 or type 373 neurono-
pathic disease who are more prone to pulmonary compli-
cations, generally showed no improvement in pulmonary 
features with ERT.
Pulmonary hypertension (PH) has been noted in some 
patients on ERT. It has been suggested that there is a predispo-
sition for PH in patients with type 1, especially in the presence 
of additional genetic factors and epigenetic modifiers.74 Others 
have suggested a causal relationship44 between PH and ERT, 
particularly among young splenectomized women, but this has 
been difficult to prove. Treatment withdrawal may be consid-
ered in these patients who evince primary-like PH and progres-
sive increases in TI gradient (30 mmHg) with ERT during 
routine echocardiographic monitoring. Alternatively, adding 
PH-specific therapy to ERT has also been beneficial.75
As implied, ERT cannot be expected to change the 
natural course of neurological progression in type 2 disease76 
or type 3 disease77 regardless of dosage regimens.Biologics: Targets & Therapy 2009:3 411
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Summary of the clinical efficacy 
of imiglucerase
In summary, and with 15 years of experience with 
imiglucerase, the important conclusion seems to be that at 
advent of therapy most patients suffer from several clinically 
relevant signs and symptoms of Gaucher disease, and that 
these gradually (2 to 5 years) improve with exposure to ERT 
so that near-normalization of many parameters is possible, 
although some parameters or perhaps some segment of the 
bell-curve of symptomatic patients, do not respond equally 
well or perhaps not even adequately. Those patients with 
neurological features will probably only see benefit in 
improved visceral and hematological signs and symptoms.
Safety of imiglucerase
Most of the side effects listed for alglucerase and imiglucerase 
during the clinical trials and afterwards, were infrequently 
observed, typically mild, and almost always transient in 
nature. This excellent safety has allowed home therapy in 
many countries,78,79 and the administration of ERT during 
pregnancy despite the original warning in the package 
insert.80,81 The development of anti-glucocerebrosidase 
antibodies has been reported to occur among 15% of 
patients;82 primarily non-neutralizing IgG antibodies.
Unresolved issues
There were some concerning issues that were raised by 
clinicians based on patient reports: some related to the preva-
lence and impact of side effects of ERT such as weight gain 
and diabetes and metabolic syndrome-like conditions;83 or 
evolution of neurological symptoms in type 1 patients;84 the 
incidence of new bony complications in treated patients;85,86 
and severe allergic reactions87 requiring pre-medication for 
infusions and the adverse related to both infusions per se and 
the pre-medications.
Recently, it has been implied that there is an increased risk 
for cancer among patients with the N370S allele88 and that 
there is also decreased survival among patients with type 1 
disease which is ascribed to cancers, as well as cardiovas-
cular and cerebrovascular events,89 the latter heretofore not 
having figured prominently as Gaucher-specific signs, and 
unexplainable based on studies of lipid-cholesterol profiles in 
Gaucher disease.90 These potentially immunologically based 
events have raised theoretical concerns about the nature of 
glucocerebroside storage and its potentially beneficial rami-
fications.91 Because of the putative association of ERT with 
increased rates of malignancy, immune mediated disorders, 
and altered metabolic pathways ERT although indicated for 
patients with moderate to severe disease, may not be justified 
in patients with very mild disease.91
The dosage controversy has never been adequately 
resolved.92,93 The first and possibly overriding concern 
was the cost, but beyond this was the question of whether 
higher doses actually translate into more effective therapy.94 
Moreover, as the above concerns about the inimical aspects 
of ERT and particularly high-dose ERT are raised, and the 
question of indications for therapy re-evaluated, the concept 
of maintenance regimens and/or (intermittent or complete) 
withdrawal95,96 and not just dose adjustments97 after achieving 
near-normalization of hematological and visceral parameters 
with ERT should also be re-considered.
Important unresolved issues 
that spur the initiatives for new 
modalities: cost
Cost remains a critical constraint in providing imiglucerase 
to symptomatic patients, although it must be noted that the 
Genzyme Corporation has been generous with a worldwide 
programs for compassionate use. However, expensive 
therapy for a potentially non-lethal disease such as type 1 
Gaucher disease has both ethical ramifications98 because of 
issues of scarce resources, as well as economic considerations 
because national health budgets99 that subsidize expensive 
therapies are prioritized by societal value systems. Cost per 
unit is high; the manufacturer recommended regimen is high-
dose; asymptomatic patients are treated prophylactically; and 
there is a commitment to life-long treatment because mainte-
nance regimens at lower doses and/or drug vacations are not 
sanctioned. Thus, a less expensive enzyme, potentially safe 
and effective as imiglucerase, would be an attractive option 
and this despite the above clinically-relevant qualifiers
Biosimilar enzymatic preparations
Both Shire Human Genetics Therapies (Cambridge, MA, 
USA) and Protalix Pharmaceuticals (Carmiel, Israel) are cur-
rently in clinical trials with respective infusible enzyme thera-
pies and are preparing New Drug Administration submissions 
to the FDA. The Shire enzyme, velaglucerase alfa, has the 
advantages of being produced in a human cell line and hav-
ing the normal human sequence100 (imiglucerase has a point 
mutation) while the Protalix enzyme uses a high-yield plant 
cell system that is easily up-scalable in disposable bioreactors 
and free from any exposure to mammalian tissues.101 Both 
are being tested at two doses and in treatment-naïve patients 
as well as in patients who had been exposed to imiglucerase; 
velaglucerase alfa also has a head-to-head comparison Biologics: Targets & Therapy 2009:3 412
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with imiglucerase at the high-dose regimen. Because being 
dependent on a single source for therapy is not desirable, even 
for rare diseases, comparable treatments should be encour-
aged. Should these biosimilars actualize their potential as 
equally safe and comparably effective as imiglucerase plus 
be less expensive, they would be well-positioned to capture 
some of the imiglucerase market share.
Other therapeutic modalities: 
substrate reduction (inhibition) 
therapy
In 1996, Radin suggested that enzyme therapy, a “spectacularly 
expensive mode of treatment should be replaceable with 
a suitable enzyme inhibitor that simply slows formation 
of the lipid, and matches the rate of synthesis with the 
rate of the defective, slowly working beta-glucosidase”.102 
The iminosugar N-butyl deoxynojirimycin (miglustat), 
an inhibitor of glucosyltransferase, the first committed 
step in the biosynthesis of glycolipids, was a harbinger of 
this new class of oral substrate inhibitors for lysosomal 
storage diseases but also indirectly introduced pharmaco-
logical chaperoning as a therapeutic modality (see below). 
Because of its more problematic safety profile, miglustat 
(Zavesca®; Actelion Pharmaceuticals) was approved by the 
EMEA (2002) only for adult patients with mild to moderate 
disease unsuitable for standard enzyme therapy and by the 
FDA (2003) with a similar caveat, for adults for whom ERT 
is not a therapeutic option. In addition, miglustat therapy 
showed improved BMD as early as 6 months after advent 
of therapy.103
In a switch-over trial that evaluated miglustat in patients 
clinically stable on imiglucerase, tolerability of miglustat and 
imiglucerase, alone and in combination, pharmacokinetic 
profile, organ reduction, and chitotriosidase activity were 
assessed. Combination therapy did not show a clinically 
significant benefit.104
In retrospect, one might raise the question why combi-
nation therapy would be recommended for type 1 disease, 
but the lack of interference between modalities may be 
noteworthy. On the other hand, for type 3 disease, small 
molecule therapy also has the potential to cross the blood-
brain barrier;105 but in the case of miglustat, it was not less 
expensive and the clinical trial failed to meet the primary end 
point and/or to make a substantial impact on neuronopathic 
features of the disease. The clinical trial recruited patients 
with type 3 disease receiving (high-dose) imiglucerase and 
added miglustat (200 mg, tid);106 but a single case report of 
an adult, after 2 years of combined miglustat (200 mg, tid) 
and imiglucerase (60 units/kg/2 weeks), showed fewer 
tonic-clonic seizures and speech improved.107
A ceramide analog as SRT
The Genzyme Corporation has begun clinical trials with 
substrate reduction therapy with GENZ 112638 a ceramide 
analog of the substrate (rather than the sugar moiety as in 
miglustat). To date, preliminary results of efficacy are very 
encouraging with improvement in key clinical parameters, 
including bone, in patients with type 1 disease. Unlike miglu-
stat, this compound is probably incapable of traversing the 
blood–brain barrier. Phase 3 trials will be recruiting in the 
2009 to 2010 quartiles.
Other therapeutic modalities:  
chaperone therapy
“Enzyme enhancement therapy” or “chaperone-mediated 
therapy” offers a novel therapeutic strategy to increase resid-
ual function of mutant proteins. Enhancement of the mutant 
enzyme is achieved by employing small molecules to prop-
erly traffic mis-folded and/or unstable mutant enzymes from 
the endoplasmic reticulum (ER)108 and prevent ER-associated 
degradation in proteasomes.109 This therapeutic approach 
is especially applicable to Gaucher disease because only a 
modest increase in residual glucocerebrosidase is sufficient 
to ameliorate the clinical phenotype.110 Small molecule chap-
erones should be able to cross the blood-brain barrier.
The first potent in vitro inhibitor of glucocerebrosi-
dase that met criteria as a pharmacological chaperone was 
isofagomine tartrate. It proved to be active-site-specific and 
capable of increasing residual glucocerebrosidase activity 
in fibroblasts (from patients with Gaucher disease) with the 
N370S mutation.111 Recent reports of the clinical safety of 
isofagomine (commercial name: Plicera™) in a phase 2 trial 
by Amicus Therapeutics (Cranberry, NJ, USA) show good 
tolerability and safety. However, the patients were those on 
ERT who discontinued for a 4-week period only in order 
to participate in the current trial; this may be insufficient to 
extrapolate that clinical parameters were maintained, since 
there was no period of ERT wash-out, and hence no informa-
tion can be derived from this trial about efficacy; this awaits 
the report of the phase 2 trial in patients naïve to treatment. 
Experience with patients who had received ERT for varying 
periods and then had withdrawn from ERT for varying peri-
ods, showed a very slow wash-out of the beneficial effects 
that had accrued from ERT.95
A second pharmacological chaperone is ambroxol hydro-
chloride (ExSAR Corporation, Princeton Junction, NJ, USA). Biologics: Targets & Therapy 2009:3 413
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A high-throughput screen of chemical compound libraries 
identified this non-carbohydrate-based inhibitory molecule 
capable of raising glucocerebrosidase activity in fibroblasts 
(from patients with Gaucher disease) with the N370S muta-
tion and the more rare F213I mutation; comparable fibroblasts 
treated with ambroxol had decreased levels of glucocerebro-
sidase in the ER and increased levels in lysosomes.112,113 
Ambroxol was originally developed as a mucolytic agent 
(Mucosolvan®; Boehringer Ingelheim GmbH, Ingelheim, 
Germany) to improve expectoration in conditions associated 
with viscid mucus114 but also promotion of prenatal lung 
maturation and prophylaxis against newborn respiratory 
distress syndrome.115 An investigator-initiated pilot study 
with ambroxol in patients with type 1 Gaucher disease was 
begun in 2009 at the Shaare Zedek Medical Center.
Diltiazem, an inhibitor of L-type Ca(2+) channels, at 
neutral pH as found in the ER was also shown to exhibit 
biochemical characteristics of a glucocerebrosidase phar-
macological chaperone: in vitro it increased enzyme activity 
in normal cells, in N370S/N370S and other Gaucher mutant 
cells.116 This drug is currently administered to patients with 
type 3 disease in the UK as another investigator-initiated 
study.
The ethical dilemma of expensive 
non-curative drugs for rare diseases
In discussing the successes of imiglucerase, it would be 
remiss not to highlight the medical ethical dilemma of an 
expensive non-curative drug such as imiglucerase for a rare 
but not lethal disease such as Gaucher disease. It is obvious 
that this allocation precludes availability of ever-more 
limited financial resources for more common and more fatal 
disorders. In 1983, the American Congress by virtue of the 
legal imperative of the Orphan Drug Act (similar legislation 
was subsequently enacted in Europe and Japan) encouraged 
clinical research into the several thousand “orphan” disorders 
each of which affects fewer than 200,000 Americans, by 
offering tax breaks and exclusive marketing rights. The 
reality of this legislation was to give pharmaceutical com-
panies brave enough to invest in “orphan drugs” that finally 
make it to the pharmacy shelf, a captive audience whose only 
drug of choice was often personally unaffordable. Although 
no society would elect to curtail treatment on the basis of cost 
in the case of abundance of resources, this is not the reality in 
any country in the world today. Thus, whereas one applauds 
the ultimately humanitarian outcome of underwriting medical 
research into diseases that had heretofore been neglected 
because few patients were involved, the phenomenon of a 
single “gold standard” treatment is no longer realistic nor 
desirable: per unit cost matters a lot. Moreover, in the case 
of type 1 Gaucher disease where patients have enjoyed imi-
glucerase therapy for 15 years, the concept of a plateauing of 
the clinical response is no longer dismissed: there are good 
responders, ie, those achieving near-normalization of the key 
clinical parameters within 2 to 5 years, and there are also 
less good responders who do not derive a complete clinical 
remission. There are those with brain, bone, and lung signs 
and symptoms that have emerged, whether before treatment 
or whether while on ERT, whose disease progresses in these 
organs and whose quality of life is considerably impaired. 
Indeed, there is the difficult question of whether ERT is 
ethically condonable in type 2 Gaucher disease.117 For this 
reason, the interest in new formulations and new modalities is 
a sign of the economics of our time, but also an appreciation 
of the fact that ERT is not the ultimately best resolution for 
all patients with the various forms of Gaucher disease.
Conclusion: hopes for the future
Clearly, all the above therapeutic modalities miss the point 
of providing a cure: although maintenance regimens have not 
been addressed, it is probable that symptomatic patients will 
continue to need specific therapy for Gaucher disease over 
the course of a lifetime. It is also manifestly clear that once 
brain, bone, and lung involvement become symptomatic, 
the probability of any of the above modalities to reverse the 
pathology is low indeed. Only gene therapy118 may prevent 
emergence of any symptoms and would be curative for all 
forms of the disease as well. Bone marrow transplantation 
(BMT) has been used in the past,119 albeit in limited cases and 
mostly in children with type 3 disease, in order to ameliorate 
the enzyme deficiency by providing enzyme competent cells 
from the donor marrow. Enzyme levels were restored and 
glucocerebroside levels in plasma were normalized one year 
after BMT in all the engrafted patients,120 but this modality 
has been abandoned in non-neuronopathic Gaucher disease 
because of its inherent risks for a non-life-threatening disor-
der. Studies of human CD34 cells were carried out to evaluate 
their potential use in a gene therapy approach to Gaucher 
disease and trials in humans were initiated.121,122 Unhappily 
progress has been erratic and new clinical trials in patients 
with Gaucher disease are not yet on the horizon. However, 
based on a new murine model of type 1 Gaucher disease and 
using low-risk conditioning regimens (non-myeloablative 
doses of busulfan) there have been encouraging data that only 
a low level of normal or gene-corrected cells with engraft-
ment can induce a beneficial therapeutic outcome.123Biologics: Targets & Therapy 2009:3 414
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